Turning Point Therapeutics Inc

TPTX NASDAQ
42.42
+0.01
+0.02%
已收盘, 16:25 08/16 EDT
开盘
42.83
昨收
42.41
最高
45.19
最低
40.69
成交量
14.77万
成交均量(3M)
16.95万
52周最高
47.72
52周最低
24.21
换手率
0.72%
市值
8.66亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Turning Point Therapeutics Inc TPTX股票价格,Turning Point Therapeutics Inc股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
展开 >

最近浏览

名称
价格
涨跌幅